Shamrock Pharmachemi Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 02-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 02-12-2024
- Company Age 43 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 94.42 Cr
as on 02-12-2024
- Revenue 13.14%
(FY 2021)
- Profit 136.67%
(FY 2021)
- Ebitda 34.49%
(FY 2021)
- Net Worth 69.98%
(FY 2021)
- Total Assets -8.37%
(FY 2021)
About Shamrock Pharmachemi
The Corporate was formerly known as Shamrock Exports Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹94.42 Cr.
Ketan Parikh and Kamlesh Khokhani serve as directors at the Company.
- CIN/LLPIN
U51900MH1981PTC024607
- Company No.
024607
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 1981
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Shamrock Pharmachemi?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamlesh Khokhani  | Director | 17-Mar-2016 | Current |
| Ketan Parikh | Director | 22-Jun-2022 | Current |
Financial Performance and Corporate Structure Insights of Shamrock Pharmachemi.
Shamrock Pharmachemi Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 13.14% increase. The company also saw a substantial improvement in profitability, with a 136.67% increase in profit. The company's net worth Soared by an impressive increase of 69.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shamrock Pharmachemi?
In 2021, Shamrock Pharmachemi had a promoter holding of 100.00%. The company had 3 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shamrock Pharmachem India Private LimitedActive 1 year 8 monthsKetan Parikh and Kamlesh Khokhani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 May 2024 | ₹9.00 M | Open |
Others Creation Date: 18 May 2023 | ₹50.00 Cr | Open |
Others Creation Date: 28 Jul 2022 | ₹1.52 Cr | Open |
How Many Employees Work at Shamrock Pharmachemi?
Shamrock Pharmachemi has a workforce of 47 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shamrock Pharmachemi, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shamrock Pharmachemi's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
